NR3C2 and heart failure: The study had to assess the effectiveness of SGLT2i in comparison with usual care that implements heart failure guidelines with dietary intervention and pharmacotherapy, including beta-blockers, ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists (MRA).